Literature DB >> 7497146

Suggested screening guidelines for familial colorectal cancer.

S V Hodgson1, D T Bishop, M G Dunlop, D G Evans, J M Northover.   

Abstract

Guidelines for screening for colorectal cancer in subjects with a positive family history of the disease, without the use of DNA based screening, are outlined. These suggestions are derived from (a) the experience of screening 644 subjects at an estimated lifetime risk of dying from colorectal cancer of 10% or more, in the St Mark's Family Cancer Clinic, over six years, and (b) a review of published studies, particularly incorporating the experience of the International Collaboration Group on Hereditary Non-polyposis Colorectal Cancer (HNPCC). Selection of subjects for surveillance depends upon the empirical evaluation of their risk of colorectal cancer, based upon family history details, with the exclusion of a diagnosis of familial adenomatous polyposis in the family. When DNA predictive tests for genes predisposing to HNPCC are available, surveillance can be directed at subjects with a germline mutation known to confer an increased genetic risk of colorectal cancer and discontinued in those at lower (or average) risk. In many subjects, however, DNA testing may still not be possible because of the failure to identify a predisposing mutation in an affected subject in their family. Any surveillance protocol can only be evaluated by long term follow up of those subjects in multiple centres.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497146     DOI: 10.1177/096914139500200112

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  7 in total

1.  Management of colorectal cancer.

Authors:  A Melville; T A Sheldon; R Gray; A Sowden
Journal:  Qual Health Care       Date:  1998-06

2.  Improving the ascertainment of families at high risk of colorectal cancer: a prospective GP register study.

Authors:  Peter W Rose; Michael Murphy; Marcus Munafo; Cyril Chapman; Neil Mortensen; Anneke Lucassen
Journal:  Br J Gen Pract       Date:  2004-04       Impact factor: 5.386

3.  Germline HNPCC gene variants have little influence on the risk for sporadic colorectal cancer.

Authors:  I P Tomlinson; N E Beck; T Homfray; C J Harocopos; W F Bodmer
Journal:  J Med Genet       Date:  1997-01       Impact factor: 6.318

4.  Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection.

Authors:  J Rüschoff; S Wallinger; W Dietmaier; T Bocker; G Brockhoff; F Hofstädter; R Fishel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

5.  Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study.

Authors:  Isis Dove-Edwin; Peter Sasieni; Joanna Adams; Huw J W Thomas
Journal:  BMJ       Date:  2005-10-21

6.  Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation.

Authors:  F E M Rijcken; H Hollema; J H Kleibeuker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 7.  Management of colorectal cancer.

Authors:  A Leslie; R J C Steele
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.